AI-Driven Longevity Research Advances and Graphene Exhibits Unprecedented Superconducting States

This category focuses on reporting global scientific and technological advancements, which generally carry a low immediate risk. The information provided is for awareness and does not include actionable advice.

📌 Key developments

• AI-Driven Longevity Vaccines Research Launched: Insilico Medicine has initiated a new research program, 'Longevity Vaccines,' utilizing generative artificial intelligence (AI) and programmable RNA medicine. The goal is to develop single-administration, self-limiting cell therapies designed to clear 'senescent cells' (old, damaged cells that stop dividing but don't die, contributing to aging and disease) and 'fibrotic cells' (cells involved in scarring), which are considered key drivers of age-related diseases. The initial focus is on rejuvenating the aging immune system. While these specific 'Longevity Vaccines' are years away from human trials or availability, Insilico Medicine already has an AI-discovered drug, Rentosertib, in Phase III clinical trials for idiopathic pulmonary fibrosis (a severe lung scarring disease), demonstrating the potential of their AI platform.
• Ozempic (Semaglutide) Shows Longevity Benefits in Older Mice: A study published in the journal Nature by researchers at the University of California, Berkeley, found that semaglutide, the active ingredient in popular weight-loss drugs like Ozempic and Wegovy, extended the lifespan of older female mice by approximately 12%. The treated mice also maintained muscle mass, improved memory, and showed reversals in several molecular signs of aging. This suggests that semaglutide could act as a 'calorie restriction mimetic,' mimicking the anti-aging effects of eating less without actual dietary restriction. It's crucial to remember this was an animal study, so these findings do not yet prove that semaglutide will have the same longevity-extending effects in humans, nor does it provide any guidance on human use for anti-aging.
• Graphene Discovered to Host Multiple Superconducting States, Strengthened by Magnetic Fields: Researchers at the Massachusetts Institute of Technology (MIT) have made a fundamental physics breakthrough, published in Nature, discovering that 'rhombohedral graphene' (a specific, layered form of graphene, a material made of a single atom-thick sheet of carbon) can host multiple 'superconducting states' simultaneously. Superconductivity is a state where electricity flows with zero resistance, meaning no energy is lost as heat. Even more surprisingly, some of these superconducting states actually became stronger when exposed to magnetic fields, which typically destroy superconductivity. This is a lab discovery, years away from practical applications, but it could pave the way for ultra-efficient electronics, advanced quantum computers, and new energy technologies.
• New Immunotherapy Gotistobart Shows Promise for Advanced Lung Cancer: Early findings (Stage 1) from the Phase 3 PRESERVE-003 trial, presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer, indicate that an investigational drug called gotistobart significantly improved survival for patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease had worsened after prior immunotherapy. Gotistobart, an 'anti-CTLA-4 antibody' (a type of immunotherapy that blocks a protein called CTLA-4 to help the immune system attack cancer), reduced the risk of death by 43% compared to standard chemotherapy. This is a late-stage human clinical trial, but these are preliminary Stage 1 results, and the drug is not yet approved or available in pharmacies.
• Hair Loss Treatments See Significant Advancements Nearing Approval: The field of hair loss treatment is experiencing notable progress. Clascoterone, a topical 'androgen receptor inhibitor' (a drug that blocks the effects of male hormones on hair follicles), showed up to a 539% relative improvement in hair count versus placebo in Phase 3 trials for 'androgenetic alopecia' (common male and female pattern baldness). Submissions for regulatory approval to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are targeted for 2026. If approved, this could be available in pharmacies in the next few years. Additionally, PP405, a topical compound from Pelage Pharmaceuticals, which aims to reactivate dormant 'hair follicle stem cells' (specialized cells that can grow new hair), showed promising results in Phase 2a trials, with 31% of patients experiencing over 20% increased hair density; Phase 3 studies are planned for 2026. This is an earlier-stage treatment, likely several years from potential availability. Furthermore, JAK inhibitors, such as ritlecitinib (Litfulo), are already approved for severe 'alopecia areata' (an autoimmune condition causing patchy hair loss), with long-term data showing sustained benefits and significant hair regrowth for many patients. Other JAK inhibitors are also in FDA review for more extensive forms of alopecia. These treatments are available now or very soon for specific autoimmune hair loss conditions.
• Supermassive Black Hole Winds Are Far More Powerful Than Previously Thought: Astronomers using the XRISM observatory discovered that powerful winds emanating from a 'supermassive black hole' (a black hole millions to billions of times the mass of our Sun, found at the center of most large galaxies) are approximately 100 times more energetic than previously estimated. These winds were observed to spread roughly 300,000 light-years, extending far beyond the black hole's host galaxy, and carry energy equivalent to billions of supernova explosions. This discovery, from Tohoku University, significantly changes our understanding of how black holes influence the evolution of galaxies and the vast regions of space around them.
• FDA Issues Warnings on Unsubstantiated Supplement Claims: In 2026, the US Food and Drug Administration (FDA) has continued to issue warning letters and safety alerts for dietary supplements making illegal claims, containing undeclared ingredients, or having inaccurate labeling. Examples include weight-loss capsules with undisclosed stimulants, joint support formulas claiming to 'treat' arthritis (which classifies them as unapproved drugs), and sleep aids with melatonin levels far exceeding label claims. This reinforces that dietary supplements do not require FDA approval before being sold, and consumers should be cautious of claims and prioritize products with independent 'third-party testing' (testing by an organization not affiliated with the manufacturer) to verify ingredients and purity.

💡 Why it matters

These developments are crucial for understanding and potentially combating age-related diseases such as Alzheimer's and dementia, diabetes, heart disease, and cancer, which are widely feared. Advances in materials science could revolutionize energy and computing, while new space observations deepen our understanding of the universe. The warnings about supplements are vital for public health and consumer protection, especially for conditions like hair loss where unproven claims are common.

🎭 People in the news

• Alex Zhavoronkov, PhD — Founder and co-CEO of Insilico Medicine, leading the AI-driven Longevity Vaccines research initiative.
• Satoshi Yamada — Assistant Professor at Tohoku University's Frontier Institute for Interdisciplinary Sciences, involved in the discovery of more powerful supermassive black hole winds.
• Long Ju — Lawrence C. and Sarah W. Biedenharn Associate Professor of Physics at MIT, whose team discovered graphene's multiple superconducting states.
• Bill Gates — Co-founder of Microsoft and philanthropist, who stated that measles eradication is currently impossible due to vaccine hesitancy in rich countries.

👀 What to watch

• Further clinical trial results for gotistobart in lung cancer and clascoterone for hair loss as they move towards potential regulatory approval.
• More details on the specific 'Longevity Vaccines' developed by Insilico Medicine as they progress towards preclinical and clinical stages.
• Continued research into the mechanisms behind semaglutide's potential longevity effects and whether these translate to humans.
• Developments in scaling up graphene production and its integration into commercial products, particularly for energy and AI applications.